Further to DrugAlert volume 802, HPS Pharmacies wish to advise that Novo Nordisk is continuing to experience a supply interruption for Ozempic® as follows:

Ozempic® 0.25/0.5mg Pen
Semaglutide 1.34mg/mL
ARTG 308324 

Ozempic® 1mg Pen
Semaglutide 1.34mg/mL
ARTG 315107 

Novo Nordisk has revised their expected return date to end-March 2023. An internationally registered brand of semaglutide 0.25mg pens and semaglutide 1mg pens has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.

For comprehensive information and updates, please go to the Ozempic (semaglutide) shortage page available on the Therapeutic Goods Administration (TGA) website.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates